Zhu Bo-Jie, Nai Guan-Ye, Pan Tian-Xiao, Ma Zhou-Fei, Huang Zi-Dong, Shi Zong-Ze, Pang Ying-Hua, Li Na, Lin Jia-Xi, Ling Gui-Mei
The Department of Chinese Medicine, The People's Hospital of Baise, Baise, China.
Department of Hematology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Ann Transl Med. 2022 Dec;10(24):1327. doi: 10.21037/atm-22-5391.
There is a lack of effective drugs for the treatment of coronary heart disease (CHD). (SL) has multiple effects, and there is no report on CHD in SL at present. The aim of this study is to explore the mechanisms of action of SL in the treatment of CHD based on network pharmacology and molecular docking technology.
The targets and active ingredients of SL were screened using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, and CHD-related targets were obtained by searching GeneCards and DisGeNet databases. The intersection of LS active ingredient targets and CHD targets was used to construct a "drug-ingredient-disease-target" network using the Cytoscape software. The STRING database was used to construct a protein-protein interaction (PPI) network, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. Key targets and core active ingredients were selected and molecular docking was performed using the AutoDock software.
According to the predicted results, a total of 134 corresponding target genes for LS, 12 active components, 1,704 CHD-related targets, and 52 intersecting targets were obtained. GO function and KEGG pathway analysis showed that the key targets were involved with signal transducer and activator of transcription 3 (), tumor protein p53 (), and vascular endothelial growth factor A (). The molecular docking results showed that the key targets bound to the important active ingredients in a stable conformation. The core active ingredients of LS in the treatment of CHD were determined to be ursolic acid, myricetin, and beta-sitosterol.
SL may act on targets such as , , and through tumor necrosis factor (TNF) signaling pathway, interleukin 17A () signaling pathway, AGE-RAGE signaling pathway in diabetic complications, and other related pathways, thereby playing a role in preventing and treating CHD.
目前治疗冠心病(CHD)缺乏有效的药物。(SL)具有多种作用,目前尚无关于SL治疗CHD的报道。本研究旨在基于网络药理学和分子对接技术探讨SL治疗CHD的作用机制。
利用中药系统药理学(TCMSP)数据库筛选SL的靶点和活性成分,通过搜索GeneCards和DisGeNet数据库获得CHD相关靶点。利用Cytoscape软件,将LS活性成分靶点与CHD靶点的交集构建“药物-成分-疾病-靶点”网络。使用STRING数据库构建蛋白质-蛋白质相互作用(PPI)网络,并进行基因本体(GO)和京都基因与基因组百科全书(KEGG)分析。选择关键靶点和核心活性成分,使用AutoDock软件进行分子对接。
根据预测结果,共获得LS对应的134个靶基因、12个活性成分以及1704个CHD相关靶点和52个交集靶点。GO功能和KEGG通路分析表明,关键靶点涉及信号转导和转录激活因子3()、肿瘤蛋白p53()和血管内皮生长因子A()。分子对接结果表明,关键靶点与重要活性成分以稳定构象结合。确定LS治疗CHD的核心活性成分为熊果酸、杨梅素和β-谷甾醇。
SL可能通过肿瘤坏死因子(TNF)信号通路、白细胞介素17A()信号通路、糖尿病并发症中的AGE-RAGE信号通路等相关通路作用于、和等靶点,从而在防治CHD中发挥作用。